The focus of research in the Fruman Lab is signal transduction in lymphocytes and leukemia cells. Our long-term goal is to define signaling components whose function is specific to particular immune cell types or responses. Our rationale is that such components could prove useful as therapeutic targets for immunological diseases and cancer. Work in our laboratory is divided into two general areas: (1) Function of PI3K/mTOR pathway components in immune cells; (2) Targeting the PI3K/mTOR pathway in leukemia and autoimmune diseases (3) Targeting BCL2-mediated survival pathways in blood cancer cells.